Upcoming Catalysts
Posted: Tue Aug 28, 2018 11:03 pm
It's been a long quiet period up until the past few days but there are a number of catalysts on the horizon. Here's a quick list of what I anticipate to be the many potentially market-moving events for GERN in the coming weeks and months:
1. 9/13 – JNJ Pharmaceutical Business Conference Call
2. 9/13-9/17 - ISH (Plenary Session: Best Abstracts – 9/13, 4:15 pm)
3. By 9/30 - JNJ Continuation Decision
4. Imetelstat clinical development plan from Continuation Decision (not sure how much of this will be released publicly)
5. Geron Opt-In Decision
6. FDA Approval of IMerge for MDS
6. FDA Approval of IMbark for MF
7. EMA Approval of IMerge for MDS
8. Phase 3 / Part 2 of IMerge for MDS (if not granted accelerated approval)
9. Any regulatory milestone for AML (Phase 2, or AA)
10. Initiation of Phase 3 trial for imetelstat in frontline treatment of MF
11. 11/1 ASH Abstracts released online
12. By 11/15 – GERN Q3 Earnings Conference Call
13. 12/1-12/4 - ASH Meeting (late-breaking abstract presentations 12/4)
14. Wildcard – Royalty payment from non-imetelstat licensing agreement with Janssen [/https://www.sec.gov/Archives/edgar/data/886744/000110465916154548/a16-17207_1ex10d1.htm]
15. Geron business development event (e.g., product in-licensing)
Certainly, some events are unlikely but others are sure to generate activity. Best wishes to all.
j6p
1. 9/13 – JNJ Pharmaceutical Business Conference Call
2. 9/13-9/17 - ISH (Plenary Session: Best Abstracts – 9/13, 4:15 pm)
3. By 9/30 - JNJ Continuation Decision
4. Imetelstat clinical development plan from Continuation Decision (not sure how much of this will be released publicly)
5. Geron Opt-In Decision
6. FDA Approval of IMerge for MDS
6. FDA Approval of IMbark for MF
7. EMA Approval of IMerge for MDS
8. Phase 3 / Part 2 of IMerge for MDS (if not granted accelerated approval)
9. Any regulatory milestone for AML (Phase 2, or AA)
10. Initiation of Phase 3 trial for imetelstat in frontline treatment of MF
11. 11/1 ASH Abstracts released online
12. By 11/15 – GERN Q3 Earnings Conference Call
13. 12/1-12/4 - ASH Meeting (late-breaking abstract presentations 12/4)
14. Wildcard – Royalty payment from non-imetelstat licensing agreement with Janssen [/https://www.sec.gov/Archives/edgar/data/886744/000110465916154548/a16-17207_1ex10d1.htm]
15. Geron business development event (e.g., product in-licensing)
Certainly, some events are unlikely but others are sure to generate activity. Best wishes to all.
j6p